Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2019-10-07 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-10-07 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically details the resignation of a Chief Medical Officer and the appointment of the CEO to assume those responsibilities temporarily. This corresponds to an announcement of changes in the company's senior management. The document length is 3253 characters, which is relatively short and focused on management changes, not a full report or financial data. Therefore, the appropriate classification is Board/Management Information (MANG).
2019-09-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a Regulation FD Disclosure about updated clinical data and a corporate presentation related to clinical trials. It references a press release, presentation posters, and a corporate presentation attached as exhibits. The document does not contain detailed financial statements or comprehensive financial analysis but rather announces clinical trial updates and investor presentation materials. The length is about 9,000 characters, which is typical for an 8-K but not a full annual or quarterly report. The nature of the content is an announcement of clinical data and investor presentation updates, fitting the category of a Regulatory Filing (RNS) as it does not meet the criteria for other more specific categories like Earnings Release or Investor Presentation itself (which would be the actual presentation document).
2019-09-03 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2019, reporting the financial results for the quarter ended June 30, 2019. It includes a press release as Exhibit 99.1 announcing quarterly financial results. The text explicitly states it is a current report on Form 8-K and the financial results are for a quarter, indicating it is an earnings release. The document length is 3779 characters, which is relatively short and primarily contains the announcement and the press release, not the full detailed financial statements or analysis. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2019-08-06 English
FORM 4
Director's Dealing
2019-06-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.